Gregg Davis

Gregg Davis has over 20 years of experience in the pharmaceutical industry. Theirmost recent role is Vice President of Business Development at Affinia Therapeutics, a position they have held since 2022. Prior to this, they were Vice President of Corporate Development at BeyondSpring and Seed Therapeutics from 2020 to 2021. From 2019 to 2020, they were Vice President of Business Development at Asklepios BioPharmaceutical, Inc. (AskBio). From 2015 to 2019, they were Vice President of Corporate and Business Development at Avadel Pharmaceuticals plc, where they were an executive committee member responsible for sourcing and managing in-licensing, out-licensing and M&A transactions. From 2013 to 2015, they were Chief Business Officer at FLAG Therapeutics, where they co-founded the company and negotiated the license agreement for two novel classes of oncology compounds. From 2010 to 2013, they were VP Corporate Development at Patheon Inc, responsible for identifying and evaluating strategic growth opportunities for the company and executing transactions. From 2002 to 2010, they were Director of Worldwide Business Development at GlaxoSmithKline. From 1999 to 2002, they were Principal at Eno River Capital, responsible for all facets of the due diligence process and involved in structuring deals, writing and negotiating term sheets and syndicating deals. Gregg also worked as a Product Manager at Amira Medical from 1998 to 1999, where they developed a forecast model and strategic and tactical sales and marketing plan.

Gregg Davis attended the University of North Carolina at Chapel Hill from 1983 to 1987, where they obtained a BA and MBA in Economics and Business. Gregg then attended UNC Kenan-Flagler Business School from 1991 to 1993.